These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 7660358)
21. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban. Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001 [TBL] [Abstract][Full Text] [Related]
22. Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model. Kornowski R; Eldor A; Werber MM; Ezov N; Zwang E; Nimrod A; Chernine A; Finkelstein A; Panet A; Laniado S; Keren G Coron Artery Dis; 1996 Dec; 7(12):903-9. PubMed ID: 9116933 [TBL] [Abstract][Full Text] [Related]
23. Low-molecular-weight heparin exerts an early antithrombotic effect in small arteries and veins following severe trauma. Zhang B; Wieslander JB Microsurgery; 1992; 13(6):295-8. PubMed ID: 1333564 [TBL] [Abstract][Full Text] [Related]
24. Modified crush-avulsion anastomosis model on the rat femoral vein. Fu K; Izquierdo R; Hubbard T; Fareed J Microsurgery; 1995; 16(8):536-41. PubMed ID: 8538430 [TBL] [Abstract][Full Text] [Related]
25. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603 [TBL] [Abstract][Full Text] [Related]
26. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris. Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862 [TBL] [Abstract][Full Text] [Related]
27. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840 [TBL] [Abstract][Full Text] [Related]
28. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study]. Huhle G; Hoffmann U; Hoffmann I; Harenberg J; Heene DL Dtsch Med Wochenschr; 2000 Jun; 125(22):686-91. PubMed ID: 10874895 [TBL] [Abstract][Full Text] [Related]
30. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model. Walenga JM; Bakhos M; Messmore HL; Koza M; Wallock M; Orfei E; Fareed J; Pifarre R Blood Coagul Fibrinolysis; 1991 Feb; 2(1):105-11. PubMed ID: 1772977 [TBL] [Abstract][Full Text] [Related]
31. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Meyer BJ; Fernández-Ortiz A; Mailhac A; Falk E; Badimon L; Michael AD; Chesebro JH; Fuster V; Badimon JJ Circulation; 1994 Nov; 90(5):2474-80. PubMed ID: 7955205 [TBL] [Abstract][Full Text] [Related]
32. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Agnelli G; Pascucci C; Cosmi B; Nenci GG Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121 [TBL] [Abstract][Full Text] [Related]
35. Microvascular repair following crush-avulsion type injury with vein grafts: effect of direct inhibitors of thrombin on patency rate. Gravvanis AI; Tsoutsos DA; Lykoudis EG; Iconomou TG; Tzivaridou DV; Papalois AE; Patralexis CG; Ioannovich JD Microsurgery; 2003; 23(4):402-7; discussion 408-9. PubMed ID: 12942534 [TBL] [Abstract][Full Text] [Related]
36. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Eriksson BI; Ekman S; Kalebo P; Zachrisson B; Bach D; Close P Lancet; 1996 Mar; 347(9002):635-9. PubMed ID: 8596376 [TBL] [Abstract][Full Text] [Related]
37. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Théroux P; Pérez-Villa F; Waters D; Lespérance J; Shabani F; Bonan R Circulation; 1995 Apr; 91(8):2132-9. PubMed ID: 7697841 [TBL] [Abstract][Full Text] [Related]
38. Topical heparin enhances patency in a rat model of arterial thrombosis. Braam MJ; Cooley BC; Gould JS Ann Plast Surg; 1995 Feb; 34(2):148-51; discussion 151-3. PubMed ID: 7741432 [TBL] [Abstract][Full Text] [Related]
39. Hirudin: clinical potential of a thrombin inhibitor. Johnson PH Annu Rev Med; 1994; 45():165-77. PubMed ID: 8198374 [TBL] [Abstract][Full Text] [Related]
40. Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model. Doutremepuich C; Lalanne MC; Doutremepuich F; Walenga J; Fareed J; Breddin HK Haemostasis; 1991; 21 Suppl 1():99-106. PubMed ID: 1894201 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]